1. What Happened at PNK in the First Half of 2025?

PNK achieved remarkable revenue growth of 49% year-over-year, reaching 11.9 billion KRW in revenue and 2.7 billion KRW in operating profit in the first half of 2025. Its core business, ‘Cosmetics Human Application Test Service,’ accounted for 82% of total revenue, driving this growth. The ‘Other Human Application Test Service’ segment also showed a promising 11.56% growth, indicating potential for business diversification.

2. Why This Performance?

PNK’s growth is closely tied to market conditions, including steady growth in the beauty and healthcare industries and increasing demand for human application testing. Trends like ‘slow aging’ and ‘clean beauty’ offer opportunities for new test development and service expansion. The growth of the home beauty device and health functional food markets also contributes positively. PNK’s differentiated competitiveness, including being the first physician-founded company in Korea, proprietary testing methods, and big data-based consulting, are also key drivers of growth.

3. What’s Next for PNK?

PNK is expected to continue its steady growth, backed by its expansion into overseas markets, technological innovation through R&D investment, and a stable financial structure (low debt ratio of 4.87% and high operating profit margin of 22.89%). However, potential risks include rising labor costs, intensifying competition, exchange rate fluctuations, and changes in the macroeconomic environment.

4. What Actions Should Investors Take?

PNK is a promising investment with strengths in benefiting from the growth of the beauty/healthcare industry, technological innovation, and a stable financial structure. However, it is crucial for investors to make informed decisions by considering potential risks such as changes in the competitive landscape and new test development.